Prostatis Group’s Stantec STN Stock Holding History

Prostatis Group’s Portfolio STN Stock Details STN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,887	Closed	-$203K	–	181
2025 Q3	$203K	Hold	1,887	–	–	0.05%	162
2025 Q2	$205K	Buy	+1,887	New	+$182K	0.06%	155

Other funds holding STN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Prostatis Group's STN Position: Q4 2025 in Review

Prostatis Group sold out of Stantec (STN) in Q4 2025, closing a stake of 1,887 shares — an estimated $203K sold.

Prostatis Group first reported a position in STN in Q2 2025 and held it in 2 quarters. The position peaked at $205K in Q2 2025. 287 funds tracked by Wall St. Rank hold STN as of Q4 2025.

Prostatis Group reported no remaining Stantec position as of Q4 2025 after selling out during the quarter.
Prostatis Group sold 1,887 Stantec shares in Q4 2025, an estimated $203K.
Prostatis Group first reported a position in Stantec in Q2 2025 and held it in 2 quarters.
Prostatis Group's Stantec position peaked at $205K in Q2 2025.
287 funds tracked by Wall St. Rank held Stantec as of Q4 2025.

Based on Prostatis Group's 13F filing for Q4 2025, filed 17 Feb 2026.